Ozempic and Wegovy Are Changing How Food Tastes Nestlé Is Reformulating Recipes to Keep Up

Nestlé is quietly rethinking some of its recipes. The reason comes down to a side effect many people don’t talk about. Food just doesn’t taste the same once you’re on a GLP-1 drug.

David Rennie, the company’s marketing chief, told The Wall Street Journal that Nestlé now works directly with people taking medications like Ozempic, Wegovy, and Mounjaro. The team wants to understand what’s going wrong with flavor. It’s not just about eating less. Something is actually shifting in how these patients perceive taste.

Research backs this up. A 2025 study found that these medications dulled all five basic taste categories in users. Sweet, salty, bitter, sour, savory: all of it comes through weaker than before. As a result, meals often start tasting flat for these patients, even when nothing about the food itself has changed.

Nestlé’s fix, at least for now, involves leaning harder on spice. Think more pepper and bolder seasoning blends. The goal is to punch through that dulled sensory response so food still feels satisfying.

Interestingly, the company won’t necessarily advertise any of this. Rennie was fairly direct about it. Not everyone wants a label announcing that a product is made for people managing obesity with medication. Plenty of patients prefer to keep that part of their life private, even while grocery shopping.

So instead of splashy rebranding, Nestlé is taking a quieter route. The company is clarifying nutrition labels and adding smaller portion options. These adjustments help without drawing attention to who they’re really for.

One product line does state its purpose openly. Nestlé built its Vital Pursuit frozen meal brand specifically for GLP-1 users. Meanwhile, subtler changes are happening across other products too. Rennie pointed to a high-protein version of Milo, the chocolate malt drink, as one example.

That protein focus isn’t random. These medications can create real nutritional gaps. Because people eat so much less, they face a higher risk of falling short on protein, vitamin B12, vitamin D, and iron. Doctors often flag protein specifically, since inadequate intake during rapid weight loss can trigger muscle loss, not just fat loss.

Snacking habits are shifting too. According to Nestlé, GLP-1 users tend to choose smaller, higher-quality treats rather than big bags of chips or family-size portions. This makes sense. When you feel satisfied faster, a giant portion loses its appeal.

None of this happens in a vacuum. Prescriptions for these drugs have surged over the past few years, and food companies are clearly paying attention. The medications carry FDA approval for obesity and type 2 diabetes, and they come with real side effects worth knowing about, including nausea and slower digestion. They also remain prescription-only, and their cost has become a major access barrier for many patients, so anyone considering one should talk to a doctor first, not rely on a headline.

Public health agencies, including the CDC, continue to track how obesity and diabetes trends evolve as GLP-1 use grows. Nestlé’s recipe tweaks represent just one piece of a much bigger shift. Across the food industry, companies are adjusting to a medication that’s changing how millions of people experience eating.